AtriCure, Inc. (NASDAQ:ATRC) CFO M. Andrew Wade sold 2,000 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $18.41, for a total value of $36,820.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shares of AtriCure, Inc. (ATRC) traded up $0.02 on Friday, hitting $18.52. The stock had a trading volume of 165,696 shares, compared to its average volume of 198,460. AtriCure, Inc. has a one year low of $14.78 and a one year high of $25.18. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.28 and a quick ratio of 1.65.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.22) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.02. AtriCure had a negative return on equity of 20.28% and a negative net margin of 19.40%. The company had revenue of $42.20 million during the quarter, compared to analysts’ expectations of $43.44 million. During the same period in the prior year, the company earned ($0.21) EPS. AtriCure’s revenue was up 10.1% compared to the same quarter last year. analysts expect that AtriCure, Inc. will post -0.96 EPS for the current year.

Several equities research analysts have weighed in on ATRC shares. Canaccord Genuity cut their target price on AtriCure from $28.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, November 2nd. Needham & Company LLC cut their target price on AtriCure from $26.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, November 2nd. TheStreet cut AtriCure from a “c-” rating to a “d+” rating in a research note on Wednesday. Zacks Investment Research upgraded AtriCure from a “sell” rating to a “hold” rating in a research note on Monday, October 2nd. Finally, ValuEngine cut AtriCure from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. AtriCure presently has a consensus rating of “Hold” and a consensus target price of $25.00.

Institutional investors and hedge funds have recently made changes to their positions in the company. US Bancorp DE lifted its stake in shares of AtriCure by 152.1% in the 2nd quarter. US Bancorp DE now owns 4,202 shares of the medical device company’s stock valued at $102,000 after acquiring an additional 2,535 shares during the last quarter. Sei Investments Co. lifted its stake in shares of AtriCure by 75.5% in the 2nd quarter. Sei Investments Co. now owns 6,933 shares of the medical device company’s stock valued at $168,000 after acquiring an additional 2,983 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of AtriCure by 3.8% in the 2nd quarter. Legal & General Group Plc now owns 8,528 shares of the medical device company’s stock valued at $208,000 after acquiring an additional 312 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new position in shares of AtriCure in the 3rd quarter valued at $205,000. Finally, Tudor Investment Corp ET AL bought a new position in AtriCure during the 2nd quarter worth $253,000. Institutional investors own 86.17% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/01/m-andrew-wade-sells-2000-shares-of-atricure-inc-atrc-stock.html.

AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.